Iterum Therapeutics (NASDAQ:ITRM) Trading Up 1.7%

Iterum Therapeutics plc (NASDAQ:ITRM) shot up 1.7% during mid-day trading on Friday . The stock traded as high as $1.23 and last traded at $1.19. 201,385 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 354,820 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Iterum Therapeutics in a research note on Friday, June 21st.

Iterum Therapeutics Price Performance

The stock has a fifty day moving average of $1.27 and a 200 day moving average of $1.45. The stock has a market cap of $19.87 million, a price-to-earnings ratio of -0.45 and a beta of 2.26.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. As a group, equities analysts expect that Iterum Therapeutics plc will post -1.76 earnings per share for the current fiscal year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.